What is Bipolar Disorder Drugs Market?
Bipolar Disorder also called maniac depression results in extreme mood swings. Having this disorder has difficulty in managing everyday tasks. The symptoms include mania, hypomania and depression. In bipolar 1, the person experiences hypomanic or depressive episodes. Whereas, in bipolar 2, the person experiences major depression that lasts at least 2 weeks. According to natural institute of mental health, each year 5.7 million adults are affected by this disorder in United States.
The market study is being classified by Type (Mood stabilizers, Antipsychotics, Antidepressant drugs and Other drugs), by Application (Hospital, Lab and Others) and major geographies with country level break-up.
Glaxo SmithKline (United Kingdom), Pfizer (United States), Janssen Pharmaceuticals (Belgium), Eli Lilly (United States), Allergan (Ireland), Novartis (Switzerland), AbbVie (United States), Otsuka (Japan), AstraZeneca (United Kingdom) and Abbott Laboratories Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Bristol-Myers Squibb Company (United States), AstraZeneca PLC (United Kingdom), Cephalon Inc. (United States) and Eli Lilly and Company (United States).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Bipolar Disorder Drugs market throughout the predicted period.
Segment Analysis
Analyst at AMA have segmented the market study of Global Bipolar Disorder Drugs market by Type, Application and Region.
On the basis of geography, the market of Bipolar Disorder Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Increase in Prevalence of Bipolar Disorder
- Need to Reduce the Burden of Disease from Bipolar Disorder
Market Trend
- Government Initiatives for Increasing Public Awareness about the Bipolar Disorder
- Advancements in Therapies of Bipolar Disorder
Restraints
- High Costs Associated with the Treatment
- Stringent Government Regulations Available
Opportunities
- Rising Awareness of Bipolar Disorder Effects
- Increasing Demand of Anti-Depressants in Developed as Well as Developing Countries
Challenges
- Lack of Awareness about the Symptoms of Bipolar Disorder
Market Leaders and some development strategies
In 2018, Glaxo SmithKline has acquired Tesaro which will strengthen its pharmaceutical business
Key Target Audience
Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organisations, Government Agencies and Organisations